Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

Summit Therapeutics SMMT reported second-quarter 2025 loss per share of 76 cents, much wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago period, the company had incurred a ...

Public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2.

Cambridge based drug sleuth Bicycle Therapeutics has extended its cash runway from mid-2027 into 2028 as it closes in on ...

Indian equity benchmarks closed lower in a volatile Tuesday session, weighed down by blue-chip bank stocks and caution ahead ...